MTORC2 explained

mTOR
Hgncid:3942
Symbol:MTOR
Altsymbols:FRAP, FRAP2, FRAP1
Entrezgene:2475
Omim:601231
Refseq:NM_004958
Uniprot:P42345
Ecnumber:2.7.11.1
Chromosome:1
Arm:p
Band:36
RICTOR
Hgncid:28611
Symbol:RICTOR
Entrezgene:253260
Refseq:NM_152756
Chromosome:5
Arm:p
Band:13.1
MLST8
Hgncid:24825
Symbol:MLST8
Entrezgene:64223
Omim:612190
Refseq:NM_022372
Uniprot:Q9BVC4
Chromosome:16
Arm:p
Band:13.3
MAPKAP1
Hgncid:18752
Symbol:MAPKAP1
Entrezgene:79109
Omim:610558
Refseq:NM_001006617.1
Uniprot:Q9BPZ7
Chromosome:9
Arm:q
Band:34.11

mTOR Complex 2 (mTORC2) is an acutely rapamycin-insensitive protein complex formed by serine/threonine kinase mTOR that regulates cell proliferation and survival, cell migration and cytoskeletal remodeling.[1] The complex itself is rather large, consisting of seven protein subunits. The catalytic mTOR subunit, DEP domain containing mTOR-interacting protein (DEPTOR), mammalian lethal with sec-13 protein 8 (mLST8, also known as GβL), and TTI1/TEL2 complex are shared by both mTORC2 and mTORC1. Rapamycin-insensitive companion of mTOR (RICTOR), mammalian stress-activated protein kinase interacting protein 1 (mSIN1), and protein observed with rictor 1 and 2 (Protor1/2) can only be found in mTORC2.[2] [3] Rictor has been shown to be the scaffold protein for substrate binding to mTORC2.[4]

Function

Though less understood than mTORC1, mTORC2 has been shown to respond to growth factors and to modulate cell metabolism and cell survival, thanks to its activation of the survival kinase Akt.[5] mTORC2 activation by growth factors is done through promotion of mTORC2-ribosome association in PI3K-dependent manner.[6] The complex also plays a role as an important regulator in the organization of the actin cytoskeleton through its stimulation of F-actin stress fibers, paxillin, RhoA, Rac1, Cdc42, and protein kinase C α (PKCα).[7]

mTORC2 also regulates cellular proliferation and metabolism, in part through the regulation of IGF-IR, InsR, Akt/PKB and the serum-and glucocorticoid-induced protein kinase SGK. mTORC2 phosphorylates the serine/threonine protein kinase Akt/PKB at a serine residue S473 as well as serine residue S450. Phosphorylation of the serine stimulates Akt phosphorylation at a threonine T308 residue by PDK1 and leads to full Akt activation.[8] [9] Curcumin inhibits both by preventing phosphorylation of the serine.[10] Moreover, mTORC2 activity has been implicated in the regulation of autophagy[11] [12] (macroautophagy[13] and chaperone-mediated autophagy).[14] In addition, mTORC2 has tyrosine kinase activity and phosphorylates IGF-IR and insulin receptor at the tyrosine residues Y1131/1136 and Y1146/1151, respectively, leading to full activation of IGF-IR and InsR.[15]

The precise localization of mTORC2 inside cells is still unclear. Some findings based on its activity point to cellular endomembranes, such as of mitochondria, as a possible site of mTORC2, whereas other suggest that the complex could be additionally located at the plasma membrane; however, this may be due to its association with Akt.[16] It is not clear if these membranes display mTORC2 activity in the cellular context, or if these pools contribute to phosphorylation of mTORC2 substrates.[17]

In neurons and neutrophils, mTORC2 facilitates actin polymerization.[18] [19] [20] Mice with reduced mTORC2 have deficient synaptic plasticity and memory.

Regulation and signaling

mTORC2 appears to be regulated by insulin, growth factors, and serum.[21] In contrast to TORC1, which is mainly stimulated by nutrients, TORC2 is mainly stimulated by growth factors.[22] Originally, mTORC2 was identified as a rapamycin-insensitive entity, as acute exposure to rapamycin did not affect mTORC2 activity or Akt phosphorylation.[8] However, subsequent studies have shown that, at least in some cell lines, chronic exposure to rapamycin, while not affecting pre-existing mTORC2s, promotes rapamycin inhibition of free mTOR molecules, thus inhibiting the formation of new mTORC2.[23] mTORC2 can be inhibited by chronic treatment with rapamycin in vivo, both in cancer cells and normal tissues such as the liver and adipose tissue.[24] [25] Torin-1 can also be used to inhibit mTORC2.[13] [26]

Upstream signaling

Similar to other PI3K regulated proteins, mTORC2 has a mSin1 subunit, which contains a phosphoinositide-binding PH domain. This domain is vital for the insulin-dependent regulation of mTORC2 activity and inhibits the catalytic activity of mTORC2 in the absence of insulin. This autoinhibition is relieved upon binding to PI3K-generated PIP3 at the plasma membrane. mSin1 subunit can also be phosphorylated by Akt. This indicates the existence of a positive feedback loop in which partial activation of Akt stimulates the activation of mTORC2. The complex then phosphorylates and fully activates Akt.[27] [28]

What might come as a surprise is that mTORC2 signaling is also regulated by mTORC1. This is due to the presence of a negative feedback loop between mTORC1 and insulin/PI3K signaling. Grb10, a negative regulator of insulin/IGF-1 receptor signaling upstream of Akt and mTORC2, is phosphorylated and therefore activated by mTORC1.[29] Additionally, some components of G protein signalling has been revealed as important regulators of mTORC2 activity as Ric-8B protein and some lipid metabolites.[30] [31] [32]

Downstream signaling

mTORC2 controls cell survival and proliferation mainly through phosphorylation of several members of the AGC (PKA/PKG/PKC) protein kinase family. mTORC2 regulates actin cytoskeleton through PKCα [33] but is able to phosphorylate other members of the PKC family that have various regulatory functions in cell migration and cytoskeletal remodeling.[34] [35] mTORC2 plays a pivotal role in phosphorylation and thus in activation of Akt, which is a vital signaling component downstream from PI3K once active,[36] and also in phosphorylation of SGK1, PKC [37] and HDACs.[38]

Role in disease

Since mTORC2 plays a crucial role in metabolic regulation, it can be linked to many human pathologies. Deregulation of mTOR signaling, including mTORC2, affects transduction of insulin signal and therefore can disrupt its biological functions and lead to metabolic disorders, such as type 2 diabetes mellitus.[39] In many types of human cancer, hyperactivation of mTORC2 caused by mutations and aberrant amplifications of mTORC2 core components is frequently observed.[40] On metabolic level, activation of mTORC2 stimulates processes related to alteration of glucose metabolism in cancer cells, altogether known as Warburg effect.[41] mTORC2-mediated lipogenesis has been linked to promotion of hepatocellular carcinoma through stimulation of glycerophospholipid and sphingolipid synthesis.[42]

Although mTORC2 is acutely insensitive to rapamycin, chronic rapamycin treatment abrogates mTORC2 signaling, leading to insulin resistance and glucose intolerance.[43] By contrast, dietary administration of Torin1, a dual mTORC1/2 inhibitor, resulted in prolonged lifespan in D. melanogaster with no reduction in fertility [44] and Akt haploinsufficiency, an mTORC2 downstream target, extended lifespan in mice.[45]

The mTORC2 pathways plays a crucial role in pathogenesis of lung fibrosis, and inhibitors of its active site such as sapanisertib (MLN-0128) have potential in the treatment of this disease and similar fibrotic lung diseases.[46]

Chronic mTORC2 activity may play a role in systemic lupus erythematosus by impairing lysosome function.[47]

Studies using mice with tissue-specific loss of Rictor, and thus inactive mTORC2, have found that mTORC2 plays a critical role in the regulation of glucose homeostasis. Liver-specific disruption of mTORC2 through hepatic deletion of the gene Rictor leads to glucose intolerance, hepatic insulin resistance, decreased hepatic lipogenesis, and decreased male lifespan.[48] [49] [50] [51] [52] Adipose-specific disruption of mTORC2 through deletion of Rictor may protect from a high-fat diet in young mice,[53] but results in hepatic steatosis and insulin resistance in older mice.[54] The role of mTORC2 in skeletal muscle has taken time to uncover, but genetic loss of mTORC2/Rictor in skeletal muscle results in decreased insulin-stimulated glucose uptake, and resistance to the effects of an mTOR kinase inhibitor on insulin resistance, highlighting a critical role for mTOR in the regulation of glucose homeostasis in this tissue.[55] [56] [57] Loss of mTORC2/Rictor in pancreatic beta cells results in reduced beta cell mass and insulin secretion, and hyperglycemia and glucose intolerance.[58] mTORC2 activity in the hypothalamus of mice increases with age, and deletion of Rictor in hypothalamic neurons promotes obesity, frailty, and shorter lifespan in mice.[59]

External links

Notes and References

  1. Saxton RA, Sabatini DM . mTOR Signaling in Growth, Metabolism, and Disease . Cell . 168 . 6 . 960–976 . March 2017 . 28283069 . 5394987 . 10.1016/j.cell.2017.02.004 .
  2. Laplante M, Sabatini DM . mTOR signaling in growth control and disease . Cell . 149 . 2 . 274–93 . April 2012 . 22500797 . 3331679 . 10.1016/j.cell.2012.03.017 .
  3. Chen X, Liu M, Tian Y, Li J, Qi Y, Zhao D, Wu Z, Huang M, Wong CC, Wang HW, Wang J, Yang H, Xu Y . 6 . Cryo-EM structure of human mTOR complex 2 . Cell Research . 28 . 5 . 518–528 . May 2018 . 29567957 . 5951902 . 10.1038/s41422-018-0029-3 .
  4. Mendoza MC, Er EE, Blenis J . The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation . Trends in Biochemical Sciences . 36 . 6 . 320–8 . June 2011 . 21531565 . 3112285 . 10.1016/j.tibs.2011.03.006 .
  5. Huang K, Fingar DC . Growing knowledge of the mTOR signaling network . Seminars in Cell & Developmental Biology . 36 . 79–90 . December 2014 . 25242279 . 4253687 . 10.1016/j.semcdb.2014.09.011 .
  6. Betz C, Stracka D, Prescianotto-Baschong C, Frieden M, Demaurex N, Hall MN . Feature Article: mTOR complex 2-Akt signaling at mitochondria-associated endoplasmic reticulum membranes (MAM) regulates mitochondrial physiology . Proceedings of the National Academy of Sciences of the United States of America . 110 . 31 . 12526–34 . July 2013 . 23852728 . 3732980 . 10.1073/pnas.1302455110 . free .
  7. Sarbassov DD, Ali SM, Kim DH, Guertin DA, Latek RR, Erdjument-Bromage H, Tempst P, Sabatini DM . 6 . Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton . Current Biology . 14 . 14 . 1296–302 . July 2004 . 15268862 . 10.1016/j.cub.2004.06.054 . 4658268 . free . 2004CBio...14.1296D .
  8. Sarbassov DD, Guertin DA, Ali SM, Sabatini DM . Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex . Science . 307 . 5712 . 1098–101 . February 2005 . 15718470 . 10.1126/science.1106148 . 2005Sci...307.1098S . 45837814 .
  9. Stephens L, Anderson K, Stokoe D, Erdjument-Bromage H, Painter GF, Holmes AB, Gaffney PR, Reese CB, McCormick F, Tempst P, Coadwell J, Hawkins PT . 6 . Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B . Science . 279 . 5351 . 710–4 . January 1998 . 9445477 . 10.1126/science.279.5351.710 . 1998Sci...279..710S .
  10. Beevers CS, Li F, Liu L, Huang S . Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells . International Journal of Cancer . 119 . 4 . 757–64 . August 2006 . 16550606 . 10.1002/ijc.21932 . 25454463 .
  11. Yang Z, Klionsky DJ . Mammalian autophagy: core molecular machinery and signaling regulation . Current Opinion in Cell Biology . 22 . 2 . 124–31 . April 2010 . 20034776 . 2854249 . 10.1016/j.ceb.2009.11.014 .
  12. Ballesteros-Álvarez J, Andersen JK . mTORC2: The other mTOR in autophagy regulation . Aging Cell . 20 . 8 . e13431 . August 2021 . 34250734 . 8373318 . 10.1111/acel.13431 .
  13. Datan E, Shirazian A, Benjamin S, Matassov D, Tinari A, Malorni W, Lockshin RA, Garcia-Sastre A, Zakeri Z . 6 . mTOR/p70S6K signaling distinguishes routine, maintenance-level autophagy from autophagic cell death during influenza A infection . Virology . 452–453 . March 2014 . 175–190 . March 2014 . 24606695 . 4005847 . 10.1016/j.virol.2014.01.008 .
  14. Arias E, Koga H, Diaz A, Mocholi E, Patel B, Cuervo AM . Lysosomal mTORC2/PHLPP1/Akt Regulate Chaperone-Mediated Autophagy . Molecular Cell . 59 . 2 . 270–84 . July 2015 . 26118642 . 4506737 . 10.1016/j.molcel.2015.05.030 .
  15. Yin Y, Hua H, Li M, Liu S, Kong Q, Shao T, Wang J, Luo Y, Wang Q, Luo T, Jiang Y . 6 . mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR . Cell Research . 26 . 1 . 46–65 . January 2016 . 26584640 . 4816127 . 10.1038/cr.2015.133 .
  16. Zoncu R, Efeyan A, Sabatini DM . mTOR: from growth signal integration to cancer, diabetes and ageing . Nature Reviews. Molecular Cell Biology . 12 . 1 . 21–35 . January 2011 . 21157483 . 3390257 . 10.1038/nrm3025 .
  17. Ebner M, Sinkovics B, Szczygieł M, Ribeiro DW, Yudushkin I . Localization of mTORC2 activity inside cells . The Journal of Cell Biology . 216 . 2 . 343–353 . February 2017 . 28143890 . 5294791 . 10.1083/jcb.201610060 .
  18. . mTOR complexes in neurodevelopmental and neuropsychiatric disorders . . 16 . 11 . 1537–1543 . 2013 . 10.1038/nn.3546 . 24165680. 7820105 .
  19. Pal . Dhiman Sankar . Banerjee . Tatsat . Lin . Yiyan . de Trogoff . Félix . Borleis . Jane . Iglesias . Pablo A. . Devreotes . Peter N. . July 2023 . Actuation of single downstream nodes in growth factor network steers immune cell migration . Developmental Cell . 58 . 13 . 1170–1188.e7 . 10.1016/j.devcel.2023.04.019 . 1534-5807 . 10524337 . 37220748. July 10, 2024 .
  20. Lin . Yiyan . Pal . Dhiman Sankar . Banerjee . Parijat . Banerjee . Tatsat . Qin . Guanghui . Deng . Yu . Borleis . Jane . Iglesias . Pablo A. . Devreotes . Peter N. . 2024-07-01 . Ras suppression potentiates rear actomyosin contractility-driven cell polarization and migration . Nature Cell Biology . en . 1–15 . 10.1038/s41556-024-01453-4 . 38951708 . 1476-4679.
  21. Frias MA, Thoreen CC, Jaffe JD, Schroder W, Sculley T, Carr SA, Sabatini DM . mSin1 is necessary for Akt/PKB phosphorylation, and its isoforms define three distinct mTORC2s . Current Biology . 16 . 18 . 1865–70 . September 2006 . 16919458 . 10.1016/j.cub.2006.08.001 . 8239162 . free . 2006CBio...16.1865F .
  22. Bockaert J, Marin P . mTOR in Brain Physiology and Pathologies . . 95 . 4 . 1157–1187 . 2015 . 10.1152/physrev.00038.2014 . 26269525.
  23. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL, Sabatini DM . 6 . Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB . Molecular Cell . 22 . 2 . 159–68 . April 2006 . 16603397 . 10.1016/j.molcel.2006.03.029 . free .
  24. Guertin DA, Stevens DM, Saitoh M, Kinkel S, Crosby K, Sheen JH, Mullholland DJ, Magnuson MA, Wu H, Sabatini DM . 6 . mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice . Cancer Cell . 15 . 2 . 148–59 . February 2009 . 19185849 . 2701381 . 10.1016/j.ccr.2008.12.017 .
  25. Lamming DW, Ye L, Katajisto P, Goncalves MD, Saitoh M, Stevens DM, Davis JG, Salmon AB, Richardson A, Ahima RS, Guertin DA, Sabatini DM, Baur JA . 6 . Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity . Science . 335 . 6076 . 1638–43 . March 2012 . 22461615 . 3324089 . 10.1126/science.1215135 . 2012Sci...335.1638L .
  26. Liu Q, Chang JW, Wang J, Kang SA, Thoreen CC, Markhard A, Hur W, Zhang J, Sim T, Sabatini DM, Gray NS . 6 . Discovery of 1-(4-(4-propionylpiperazin-1-yl)-3-(trifluoromethyl)phenyl)-9-(quinolin-3-yl)benzo[h][1,6]naphthyridin-2(1H)-one as a highly potent, selective mammalian target of rapamycin (mTOR) inhibitor for the treatment of cancer . Journal of Medicinal Chemistry . 53 . 19 . 7146–55 . October 2010 . 20860370 . 3893826 . 10.1021/jm101144f .
  27. Liu P, Gan W, Chin YR, Ogura K, Guo J, Zhang J, Wang B, Blenis J, Cantley LC, Toker A, Su B, Wei W . 6 . PtdIns(3,4,5)P3-Dependent Activation of the mTORC2 Kinase Complex . Cancer Discovery . 5 . 11 . 1194–209 . November 2015 . 26293922 . 4631654 . 10.1158/2159-8290.CD-15-0460 .
  28. Yang G, Murashige DS, Humphrey SJ, James DE . A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation . Cell Reports . 12 . 6 . 937–43 . August 2015 . 26235620 . 10.1016/j.celrep.2015.07.016 . free . 11858/00-001M-0000-0028-463C-B . free .
  29. Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, Peterson TR, Choi Y, Gray NS, Yaffe MB, Marto JA, Sabatini DM . 6 . The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling . Science . 332 . 6035 . 1317–22 . June 2011 . 21659604 . 3177140 . 10.1126/science.1199498 . 2011Sci...332.1317H .
  30. Nagai MH, Xavier VP, Gutiyama LM, Machado CF, Reis AH, Donnard ER, Galante PA, Abreu JG, Festuccia WT, Malnic B . 6 . Depletion of Ric-8B leads to reduced mTORC2 activity . PLOS Genetics . 16 . 5 . e1008255 . May 2020 . 32392211 . 10.1371/journal.pgen.1008255 . 7252638 . free .
  31. Mullins GR, Wang L, Raje V, Sherwood SG, Grande RC, Boroda S, Eaton JM, Blancquaert S, Roger PP, Leitinger N, Harris TE . 6 . Catecholamine-induced lipolysis causes mTOR complex dissociation and inhibits glucose uptake in adipocytes . Proceedings of the National Academy of Sciences of the United States of America . 111 . 49 . 17450–5 . December 2014 . 25422441 . 10.1073/pnas.1410530111 . 4267365 . 2014PNAS..11117450M . free .
  32. Zhang C, Wendel AA, Keogh MR, Harris TE, Chen J, Coleman RA . Glycerolipid signals alter mTOR complex 2 (mTORC2) to diminish insulin signaling . Proceedings of the National Academy of Sciences of the United States of America . 109 . 5 . 1667–72 . January 2012 . 22307628 . 10.1073/pnas.1110730109 . 3277174 . 2012PNAS..109.1667Z . free .
  33. Chen J, Holguin N, Shi Y, Silva MJ, Long F . mTORC2 signaling promotes skeletal growth and bone formation in mice . Journal of Bone and Mineral Research . 30 . 2 . 369–78 . February 2015 . 25196701 . 4322759 . 10.1002/jbmr.2348 .
  34. Cameron AJ, Linch MD, Saurin AT, Escribano C, Parker PJ . mTORC2 targets AGC kinases through Sin1-dependent recruitment . The Biochemical Journal . 439 . 2 . 287–97 . October 2011 . 21806543 . 10.1042/BJ20110678 .
  35. Gan X, Wang J, Wang C, Sommer E, Kozasa T, Srinivasula S, Alessi D, Offermanns S, Simon MI, Wu D . 6 . PRR5L degradation promotes mTORC2-mediated PKC-δ phosphorylation and cell migration downstream of Gα12 . Nature Cell Biology . 14 . 7 . 686–96 . May 2012 . 22609986 . 3389271 . 10.1038/ncb2507 .
  36. Jhanwar-Uniyal M, Amin AG, Cooper JB, Das K, Schmidt MH, Murali R . Discrete signaling mechanisms of mTORC1 and mTORC2: Connected yet apart in cellular and molecular aspects . Advances in Biological Regulation . 64 . 39–48 . May 2017 . 28189457 . 10.1016/j.jbior.2016.12.001 .
  37. Linke M, Fritsch SD, Sukhbaatar N, Hengstschläger M, Weichhart T . mTORC1 and mTORC2 as regulators of cell metabolism in immunity . FEBS Letters . 591 . 19 . 3089–3103 . October 2017 . 28600802 . 6322652 . 10.1002/1873-3468.12711 .
  38. Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, Iwanami A, Liu F, Villa GR, Gu Y, Campos C, Zhu S, Yang H, Yong WH, Cloughesy TF, Mellinghoff IK, Cavenee WK, Shaw RJ, Mischel PS . 6 . mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc . Cell Metabolism . 18 . 5 . 726–39 . November 2013 . 24140020 . 3840163 . 10.1016/j.cmet.2013.09.013 .
  39. Luo Y, Xu W, Li G, Cui W . Weighing In on mTOR Complex 2 Signaling: The Expanding Role in Cell Metabolism . Oxidative Medicine and Cellular Longevity . 2018 . 7838647 . 2018-10-30 . 30510625 . 6232796 . 10.1155/2018/7838647 . free .
  40. Grabiner BC, Nardi V, Birsoy K, Possemato R, Shen K, Sinha S, Jordan A, Beck AH, Sabatini DM . 6 . A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity . Cancer Discovery . 4 . 5 . 554–63 . May 2014 . 24631838 . 4012430 . 10.1158/2159-8290.CD-13-0929 .
  41. Masui K, Cavenee WK, Mischel PS . mTORC2 in the center of cancer metabolic reprogramming . Trends in Endocrinology and Metabolism . 25 . 7 . 364–73 . July 2014 . 24856037 . 4077930 . 10.1016/j.tem.2014.04.002 .
  42. Guri Y, Colombi M, Dazert E, Hindupur SK, Roszik J, Moes S, Jenoe P, Heim MH, Riezman I, Riezman H, Hall MN . 6 . mTORC2 Promotes Tumorigenesis via Lipid Synthesis . Cancer Cell . 32 . 6 . 807–823.e12 . December 2017 . 29232555 . 10.1016/j.ccell.2017.11.011 . free .
  43. Maiese K . New Insights for nicotinamide: Metabolic disease, autophagy, and mTOR . Frontiers in Bioscience . 25 . 11 . 1925–1973 . June 2020 . 32472766 . 7265993 . 10.2741/4886 .
  44. Mason JS, Wileman T, Chapman T . Lifespan extension without fertility reduction following dietary addition of the autophagy activator Torin1 in Drosophila melanogaster . PLOS ONE . 13 . 1 . e0190105 . 2018-01-12 . 29329306 . 5766080 . 10.1371/journal.pone.0190105 . 2018PLoSO..1390105M . free .
  45. Nojima A, Yamashita M, Yoshida Y, Shimizu I, Ichimiya H, Kamimura N, Kobayashi Y, Ohta S, Ishii N, Minamino T . 6 . Haploinsufficiency of akt1 prolongs the lifespan of mice . PLOS ONE . 8 . 7 . e69178 . 2013-07-30 . 23935948 . 3728301 . 10.1371/journal.pone.0069178 . 2013PLoSO...869178N . Sadoshima J . free .
  46. Chang W, Wei K, Ho L, Berry GJ, Jacobs SS, Chang CH, Rosen GD . A critical role for the mTORC2 pathway in lung fibrosis . PLOS ONE . 9 . 8 . e106155 . 2014-08-27 . 25162417 . 4146613 . 10.1371/journal.pone.0106155 . 2014PLoSO...9j6155C . Mora A . free .
  47. Monteith AJ, Vincent HA, Kang S, Li P, Claiborne TM, Rajfur Z, Jacobson K, Moorman NJ, Vilen BJ . 6 . mTORC2 Activity Disrupts Lysosome Acidification in Systemic Lupus Erythematosus by Impairing Caspase-1 Cleavage of Rab39a . Journal of Immunology . 201 . 2 . 371–382 . July 2018 . 29866702 . 6039264 . 10.4049/jimmunol.1701712 .
  48. Hagiwara A, Cornu M, Cybulski N, Polak P, Betz C, Trapani F, Terracciano L, Heim MH, Rüegg MA, Hall MN . 6 . Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c . Cell Metabolism . 15 . 5 . 725–38 . May 2012 . 22521878 . 10.1016/j.cmet.2012.03.015 . free .
  49. Yuan M, Pino E, Wu L, Kacergis M, Soukas AA . Identification of Akt-independent regulation of hepatic lipogenesis by mammalian target of rapamycin (mTOR) complex 2 . The Journal of Biological Chemistry . 287 . 35 . 29579–88 . August 2012 . 22773877 . 3436168 . 10.1074/jbc.M112.386854 . free .
  50. Lamming DW, Demirkan G, Boylan JM, Mihaylova MM, Peng T, Ferreira J, Neretti N, Salomon A, Sabatini DM, Gruppuso PA . 6 . Hepatic signaling by the mechanistic target of rapamycin complex 2 (mTORC2) . FASEB Journal . 28 . 1 . 300–15 . January 2014 . 24072782 . 3868844 . 10.1096/fj.13-237743 . free .
  51. Lamming DW, Mihaylova MM, Katajisto P, Baar EL, Yilmaz OH, Hutchins A, Gultekin Y, Gaither R, Sabatini DM . 6 . Depletion of Rictor, an essential protein component of mTORC2, decreases male lifespan . Aging Cell . 13 . 5 . 911–7 . October 2014 . 25059582 . 4172536 . 10.1111/acel.12256 .
  52. Arriola Apelo SI, Lin A, Brinkman JA, Meyer E, Morrison M, Tomasiewicz JL, Pumper CP, Baar EL, Richardson NE, Alotaibi M, Lamming DW . 6 . Ovariectomy uncouples lifespan from metabolic health and reveals a sex-hormone-dependent role of hepatic mTORC2 in aging . eLife . 9 . e56177 . 2020-07-28 . 32720643 . 10.7554/eLife.56177 . 7386906 . free .
  53. Cybulski N, Polak P, Auwerx J, Rüegg MA, Hall MN . mTOR complex 2 in adipose tissue negatively controls whole-body growth . Proceedings of the National Academy of Sciences of the United States of America . 106 . 24 . 9902–7 . June 2009 . 19497867 . 2700987 . 10.1073/pnas.0811321106 . 2009PNAS..106.9902C . free .
  54. Kumar A, Lawrence JC, Jung DY, Ko HJ, Keller SR, Kim JK, Magnuson MA, Harris TE . 6 . Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism . Diabetes . 59 . 6 . 1397–406 . June 2010 . 20332342 . 2874700 . 10.2337/db09-1061 .
  55. Kumar A, Harris TE, Keller SR, Choi KM, Magnuson MA, Lawrence JC . Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances Basal glycogen synthase activity . Molecular and Cellular Biology . 28 . 1 . 61–70 . January 2008 . 17967879 . 2223287 . 10.1128/MCB.01405-07 .
  56. Kleinert M, Sylow L, Fazakerley DJ, Krycer JR, Thomas KC, Oxbøll AJ, Jordy AB, Jensen TE, Yang G, Schjerling P, Kiens B, James DE, Ruegg MA, Richter EA . 6 . Acute mTOR inhibition induces insulin resistance and alters substrate utilization in vivo . Molecular Metabolism . 3 . 6 . 630–41 . September 2014 . 25161886 . 4142396 . 10.1016/j.molmet.2014.06.004.
  57. Kennedy BK, Lamming DW . The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging . Cell Metabolism . 23 . 6 . 990–1003 . June 2016 . 27304501 . 4910876 . 10.1016/j.cmet.2016.05.009 .
  58. Gu Y, Lindner J, Kumar A, Yuan W, Magnuson MA . Rictor/mTORC2 is essential for maintaining a balance between beta-cell proliferation and cell size . Diabetes . 60 . 3 . 827–37 . March 2011 . 21266327 . 3046843 . 10.2337/db10-1194 .
  59. Chellappa K, Brinkman JA, Mukherjee S, Morrison M, Alotaibi MI, Carbajal KA, Alhadeff AL, Perron IJ, Yao R, Purdy CS, DeFelice DM, Wakai MH, Tomasiewicz J, Lin A, Meyer E, Peng Y, Arriola Apelo SI, Puglielli L, Betley JN, Paschos GK, Baur JA, Lamming DW . 6 . Hypothalamic mTORC2 is essential for metabolic health and longevity . Aging Cell . 18 . 5 . e13014 . October 2019 . 31373126 . 6718533 . 10.1111/acel.13014 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "MTORC2".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.